Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia

Novo NordiskNovo Nordisk announced today the start of a global survey into the psychological and social effects of haemophilia. The study, named HERO (Haemophilia Experiences, Results and Opportunities), will assess factors such as the attitudes of patients and their families to diagnosis and treatment, their aspirations and the social context of haemophilia. The study will include responses from over 1,300 people from 12 countries, and is the largest international research project ever carried out into the social and psychological impact of this condition.

The launch of the study marks World Haemophilia Day April 17 and the first findings will be presented at the World Federation of Haemophilia Congress in Buenos Aires, Argentina from 10 to 14 July 2010.

The study is divided into two phases. The first phase, based on 150 face-to-face interviews, will identify the most common issues affecting the haemophilia community. The second phase, based on a much larger data sample from 1,200 respondents, will illustrate how many people actually feel affected by the identified issues.

A range of psychosocial issues are currently discussed within the haemophilia community such as lack of self-esteem, impact on family life, living with pain and fear of a future with disabilities.

"Haemophilia has far-reaching consequences beyond the physical impact of the condition for people with haemophilia, their families and the people treating the condition," said Charlotte Ersbøll, corporate vice president for Global Stakeholder Engagement at Novo Nordisk. "This new programme will help us to better understand these broader effects on the haemophilia community."

"We are here to improve the lives of people with haemophilia and it is essential that their voice is heard," commented Frederica Cassis, psychologist at the Haemophilia Center of the Hospital das Clinicas, São Paulo, Brazil. "This unique study will give us valuable insights into the broad impact of this condition and will provide us with new tools to deal with the barriers of further improving haemophilia care."

About haemophilia
Haemophilia is a rare blood clotting disorder. Internal bleeding into the joints, muscles and other tissues can cause severe pain, joint damage and disability. The worldwide incidence of haemophilia A is approximately one case per 5,000 males, approximately 30% of whom have no family history. Haemophilia B occurs in one case per 25,000 males and represents 20–25% of all patients with haemophilia. It is estimated that around 400,000 males have haemophilia A or B.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]